HomeAbout

TL;DR CNBC


Viking Therapeutics stock jumps 90% after positive weight loss drug trial results - TL;DR CNBC

Viking Therapeutics stock jumps 90% after positive weight loss drug trial results

Publishing timestamp: 2024-02-27 11:13:40


Summary

Viking Therapeutics' shares soared after their weight loss drug showed promising results in a mid-stage trial. Analysts believe the weight loss drug industry could grow to a $100 billion market by the end of the decade. Larger pharmaceutical companies like Pfizer may consider acquiring Viking Therapeutics. The drug, VK2735, showed significant weight loss results in patients with obesity or who are overweight. The company plans to present full Phase 2 data and meet with the FDA to discuss further development steps.


Sentiment: POSITIVE

Tickers: LLYPFEVKTX

Keywords: business newspharmaceuticalsbusinessbiotech and pharmaceuticalsviking therapeutics incpfizer incbiotechnologyhealth care industryeli lilly and cobreaking news

Source: https://www.cnbc.com/2024/02/27/viking-therapeutics-weight-loss-drug-shows-promising-trial-results.html


Developed by Leo Phan